{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=34&q=advanced+solid+tumors", "query": { "q": "advanced solid tumors", "condition": "Cancer", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 5926, "total_pages": 593, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=35&q=advanced+solid+tumors&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=33&q=advanced+solid+tumors&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T01:10:28.125Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03431948", "title": "Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cabiralizumab", "type": "DRUG" }, { "name": "Urelumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2018-03-15", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2023-02-16", "last_synced_at": "2026-10-16T01:10:28.125Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03431948" }, { "nct_id": "NCT01991678", "title": "A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment" ], "interventions": [ { "name": "145 mg/m2 NKTR 102", "type": "DRUG" }, { "name": "120 mg/m2 NKTR 102", "type": "DRUG" }, { "name": "50 mg/m2 NKTR 102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2013-11", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2017-10-06", "last_synced_at": "2026-10-16T01:10:28.125Z", "location_count": 3, "location_summary": "Los Angeles, California • San Francisco, California • Cleveland, Ohio", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01991678" }, { "nct_id": "NCT05014815", "title": "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)", "Nonsmall Cell Lung Cancer, Stage IIIB", "Nonsmall Cell Lung Cancer, Stage IV" ], "interventions": [ { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2021-11-16", "completion_date": "2024-09-04", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-10-16T01:10:28.125Z", "location_count": 11, "location_summary": "Los Angeles, California • Iowa City, Iowa • Las Vegas, Nevada + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014815" }, { "nct_id": "NCT04843709", "title": "A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "MRG004A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lepu Biopharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2021-07-26", "completion_date": "2024-07-26", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-16T01:10:28.125Z", "location_count": 6, "location_summary": "Orange, California • New York, New York • Canton, Ohio + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Canton", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Gettysburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04843709" }, { "nct_id": "NCT03928314", "title": "Study of ORIC-101 in Combination With Anticancer Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "ORIC-101", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORIC Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2019-05-02", "completion_date": "2023-12-04", "has_results": false, "last_update_posted_date": "2023-12-15", "last_synced_at": "2026-10-16T01:10:28.125Z", "location_count": 12, "location_summary": "Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03928314" }, { "nct_id": "NCT06725758", "title": "A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "ODM-212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orion Corporation, Orion Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 315, "start_date": "2023-10-26", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-16T01:10:28.125Z", "location_count": 8, "location_summary": "Los Angeles, California • Orange, California • St Louis, Missouri + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06725758" }, { "nct_id": "NCT04111458", "title": "A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, KRAS Mutation; SOS1" ], "interventions": [ { "name": "BI 1701963", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2019-11-04", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-16T01:10:28.125Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Charlotte, North Carolina • Nashville, Tennessee + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04111458" }, { "nct_id": "NCT02040558", "title": "Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "MNK-010", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mallinckrodt", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2013-07", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2017-04-05", "last_synced_at": "2026-10-16T01:10:28.125Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02040558" }, { "nct_id": "NCT05573555", "title": "TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "ARV-471", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-03-01", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-16T01:10:28.125Z", "location_count": 20, "location_summary": "Palo Alto, California • San Francisco, California • Tampa, Florida + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05573555" }, { "nct_id": "NCT05374538", "title": "VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "VIC-1911", "type": "DRUG" }, { "name": "sotorasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vitrac Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-11-09", "completion_date": "2023-08-26", "has_results": true, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-10-16T01:10:28.125Z", "location_count": 5, "location_summary": "Sacramento, California • North Haven, Connecticut • Atlanta, Georgia + 2 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05374538" } ] }